These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26200834)

  • 21. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The sensitivity and specificity of estrogen receptor, progesterone receptor and HER-2 staining in core biopsies of invasive breast carcinomas.
    Frederik P; Cecile C; Tjalma WA
    Breast J; 2007; 13(4):436-7. PubMed ID: 17593058
    [No Abstract]   [Full Text] [Related]  

  • 23. Quality control program of steroid receptor assays: an international study.
    Vermousek I; Számel I; Goerlich M; Brdar B; Cvrtila D; Graf D; Padovan R; Paszko Z; Safarcík K
    Neoplasma; 1992; 39(1):65-9. PubMed ID: 1382235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies.
    Suzuki R; Orsini N; Mignone L; Saji S; Wolk A
    Int J Cancer; 2008 Apr; 122(8):1832-41. PubMed ID: 18067133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program.
    Hung T; Wolber R; Garratt J; Kalloger S; Gilks CB
    Pathology; 2010 Dec; 42(7):637-42. PubMed ID: 21080872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical evaluation of hormone receptor for routine practice of breast cancer: highly sensitive procedures significantly contribute to the correlation with biochemical assays.
    Umemura S; Itoh H; Ohta M; Suzuki Y; Kubota M; Tokuda Y; Tajima T; Osamura RY
    Appl Immunohistochem Mol Morphol; 2003 Mar; 11(1):62-72. PubMed ID: 12610359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Reliability of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression in breast cancer evaluated by immunohistochemistry].
    Gu CS; Ying M; He YJ; Liu YQ; Dong B; Ouyang T; Lu AP
    Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(32):2571-3. PubMed ID: 24351599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progesterone, glucocorticoid, but not estrogen receptor mRNA is altered in breast cancer stroma.
    Smith RA; Lea RA; Weinstein SR; Griffiths LR
    Cancer Lett; 2007 Sep; 255(1):77-84. PubMed ID: 17512111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standardizing Immunohistochemistry: A New Reference Control for Detecting Staining Problems.
    Sompuram SR; Vani K; Tracey B; Kamstock DA; Bogen SA
    J Histochem Cytochem; 2015 Sep; 63(9):681-90. PubMed ID: 25940339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes.
    Cheung CC; Garratt J; Won J; Cutz JC; Gilks BC; Tsao M; Torlakovic EE
    Appl Immunohistochem Mol Morphol; 2015; 23(10):677-81. PubMed ID: 26551338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The precarious path to diagnostic accuracy: the Ontario hormone receptor guideline.
    Hughes-Davies L
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):682-3. PubMed ID: 23031346
    [No Abstract]   [Full Text] [Related]  

  • 32. A validation study of quantum dot multispectral imaging to evaluate hormone receptor status in ductal carcinoma in situ of the breast.
    Yu J; Monaco SE; Onisko A; Bhargava R; Dabbs DJ; Cieply KM; Fine JL
    Hum Pathol; 2013 Mar; 44(3):394-401. PubMed ID: 23039940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry.
    Radhika K; Prayaga AK
    Indian J Cancer; 2010; 47(2):148-50. PubMed ID: 20448377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pure and mixed hormone receptor positive breast tumors: are they different from therapeutic point of view?
    Altundag K; Altundag O; Gunduz E; Silay YS; Boruban C
    Med Hypotheses; 2005; 65(1):194. PubMed ID: 15893141
    [No Abstract]   [Full Text] [Related]  

  • 36. Academic and nonacademic laboratories perform equally on CIQC immunohistochemistry proficiency testing.
    Chen ZW; Neufeld H; Copete MA; Garratt J; Gilks CB; Torlakovic EE
    Am J Clin Pathol; 2013 Jul; 140(1):55-60. PubMed ID: 23765534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of estrogen and progesterone receptor in primary breast cancer.
    Clark GM; McGuire WL; Hubay CA; Pearson OH; Carter AC
    Prog Clin Biol Res; 1983; 132E():183-90. PubMed ID: 6647468
    [No Abstract]   [Full Text] [Related]  

  • 38. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
    Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
    Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.